Veru Inc. (NASDAQ: VERU) announced it has completed enrollment in its Phase 2b PLATEAU clinical trial, which exceeded its target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE